



Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 06 July 2022.

I am pleased to confirm the following.

1.In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?

Please see attached document.

2.Of these five, how many of each received the following products:

- Adalimumab (Humira)
- Adalimumab Biosimilar
- Etanercept (Enbrel)
- Etanercept Biosimilar
- Infliximab (Remicade)
- Infliximab biosimilar
- Golimumab (Simponi)
- Tofacitinib (Xeljanz)
- Ustekinumab (Stelara)
- Vedolizumab (Entyvio)
- Filgotinib (Jyseleca)
- Abatacept (Orencia)
- Baricitinib (Olumiant)
- Certolizumab Pegol (Cimzia)
- Rituximab (MabThera)
- Rituximab Biosimilar
- Tocilizumab (RoActemra)
- Sarilumab (Kevzara)
- Apremilast (Otezla)
- Secukinumab (Cosentyx)
- Isekizumab (Taltz)
- Guselkumab (Tremfya)
- Brodalumab (Kyntheum)
- Risankizumab (Skyrizi)
- Tildrakizumab (llumetri)
- Upadacitinib (Rinvog)
- Bimekizumab (Bimzelx)

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.

Chief Executive: Professor Joe Harrison Chair: Alison Davis 3.Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).

4.Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

- AxSPA
- PsA
- PsO

The Trust is unable to answer questions 2, 3 and 4 as they're indication specific.

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

> Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.